MedPath

Classroom Air Purifiers for Reducing School Absence: a Cluster-randomized, Parallel, Two-arm, Group Sequential Superiority Trial

Not Applicable
Not yet recruiting
Conditions
Asenteeism
Registration Number
NCT07119333
Lead Sponsor
Norwegian Institute of Public Health
Brief Summary

Background

Respiratory infections like influenza and SARS-CoV-2 pose significant global health risks due to their high transmissibility and severity. SARS-CoV-2 has caused over 7 million deaths worldwide, and the Lancet Commission estimates a \>20% chance of a similar respiratory virus pandemic within a decade. Schools, often poorly ventilated, are high-risk settings for transmission. While COVID-19 school closures may have reduced transmission, they likely caused learning loss, mental health issues, and increased burdens on parents and caregivers. Air purifiers with HEPA filters may offer a non-disruptive mitigation strategy, but the evidence to support their effectiveness in reducing viral transmission is weak. This protocol describes a cluster-randomised, parallel, two-arm, group sequential superiority trial with an interim analysis-to allow early stopping for efficacy or futility-to estimate the effect of portable air purifiers with HEPA filters in primary school classrooms on student absenteeism.

Research Questions

The primary question is whether installing and operating air purifiers with HEPA-filters (intervention) reduce student absenteeism (primary outcome) compared to sham air purifiers (control). Secondary questions examine whether the intervention reduces teacher absenteeism due to respiratory infections, rate and 12-week risk of self-reported respiratory infections among teachers, and teachers' perceived air quality compared to sham air purifiers. If the trial estimates a statistically significant effect for the primary outcome, a cost-consequence analysis will evaluate the direct and indirect costs associating with operating air purifiers against the potential benefits of reduced student and teacher absenteeism. A process evaluation will explore mechanisms of effect.

Methods and Analysis

This group sequential trial will randomize schools (clusters) 1:1 to intervention or control arms in two stages: winter 2025/2026 (N = 32 schools; \~736 students) and winter 2026/2027 (N = 32 schools; \~690 students). Eligible schools must have classrooms suitable for portable air purifiers, \>10 students in grades 5-7 (typically aged 10-13 years), and principal consent. Intervention and control classrooms will each receive two portable air purifiers with HEPA-filters operating at a performance equivalent to 3.0 and 0.3 air changes per hour, respectively, with control purifiers acting as shams.

Outcomes will be measured during and at the end of a 12-week period. The primary outcome is student absenteeism, measured as full child-days of absence aggregated at the class level. An interim analysis is planned at the end of the first stage, with error-spending O'Brien-Fleming stopping boundaries that are binding for efficacy and nonbinding for futility.

The primary estimand is the marginal incidence rate ratio of student absences, estimated using generalized estimating equations with a negative binomial model to account for overdispersion. The group sequential test p-value will determine stopping and statistical significance. Treatment effects will be estimated using cluster-bootstrapped confidence intervals adjusted to provide strong control on overall type I and II error probabilities, and a bias correction will be applied if the trial is stopped early for efficacy. All analyses will follow the intention-to-treat principle.

Ethics and Dissemination

The trial has been approved by the Regional Committees for Medical and Health Research Ethics and the National Research Ethics Committee. Results will be shared with stakeholders, participants, and the public through academic journals, conferences, and social media.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
62
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Primary Outcome Measures
NameTimeMethod
Student absenteeismFrom enrollment to the end of intervention at 12 weeks

The primary outcome is the number of student-days of absence per classroom, measured each week. We will define a student day of absence as a day for which a student is absent for the entire day. We will not distinguish between the specific students who are absent (i.e., two days of absence will be counted for one student who is absent on two days, and for two students absent for one day each).

Secondary Outcome Measures
NameTimeMethod
Self-reported absence due to respiratory infections among teachersFrom enrollment to the end of intervention at 12 weeks

We will measure the number of teacher-days of work absence (sick leave) due to self-reported respiratory infection each week. We will ask teachers "Did you experience symptoms of a cold, COVID-19 or the flu last week?". Teachers who answer "Yes" to this question, will be asked to specify the symptoms they experienced (sneezing, nasal obstruction, nasal discharge, sore throath, cough, headache, fever or general discomfort) and rate each symptom from 0 to 3, where 0 = absent, 1 = mild, 2 = moderate, 3 = severe, in accordance with the Jackson index. They will then report the number of days they experienced these symptoms (ranging from 1 to 7 days), before answering "How many days were you absent from work last week due to respiratory infection?"; their response to this question will be used to measure number of days of absence. A count of zero days will be assigned to teachers answering "No" to the first question.

Incidence of self-reported respiratory symptoms consistent with respiratory infections among teachersFrom enrollment to the end of the intervention at 12 weeks

We will assess incidents of respiratory symptoms consistent with respiratory infections among teachers using self-reported data collected weekly. We define an incident as a period during which a teacher reports symptoms for at least two consecutive calendar days, preceded and followed by at least 7 symptom-free calendar days. We define symptoms of respiratory infection as meeting all four of the following criteria:

1. Answering "yes" to the question "Did you experience symptoms of a cold, COVID-19 or the flu last week?".

2. Reporting at least one of the following symptoms: nasal obstruction (plugged or congested), nasal discharge (runny nose), sneezing or sore throat, in the last week;

3. Scoring at least four points on the Jackson scale (as assessed for the preceding week);

4. Reporting that they have experienced at least one of the reported symptoms for at least two consecutive days in the last week.

This case definition largely mimics the Wisconsin Upper Respiratory Sy

Teachers reporting respiratory infectionsFrom enrollment to the end of the intervention at 12 weeks

We will assess respiratory infection as a dichotomous outcome for each teacher, based on whether they meet the case definition at any point during the 12-week follow-up.

Teacher perceptions of air quality in classroomsFrom enrollment to the end of the intervention at 12 weeks

We will assess teachers' perceptions of classroom air quality at the end of follow-up using the MM040 questionnaire: teachers will report whether they have experienced drafts, high room temperature, low room temperature, fluctuating room temperature, stuffy or "bad" air, dry air, unpleasant odours, noise, or dust in the air during follow-up. The response options will be: "Yes, often (every week)," "Yes, occasionally," or "No, never".

Adverse eventsFrom enrollment to the end of the intervention at 12 weeks

We define an adverse event as any significant disruption to lessons, or any accident or injury, that is attributable to the intervention or control. We will instruct school principals and teachers to report such events.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.